GSA Capital Partners LLP Buys 450,203 Shares of MacroGenics, Inc. $MGNX

GSA Capital Partners LLP grew its stake in shares of MacroGenics, Inc. (NASDAQ:MGNX) by 740.5% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 511,004 shares of the biopharmaceutical company’s stock after acquiring an additional 450,203 shares during the period. GSA Capital Partners LLP owned about 0.81% of MacroGenics worth $823,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of MGNX. Jane Street Group LLC grew its position in shares of MacroGenics by 207.7% during the 2nd quarter. Jane Street Group LLC now owns 758,204 shares of the biopharmaceutical company’s stock valued at $917,000 after acquiring an additional 511,777 shares during the period. Squarepoint Ops LLC grew its position in shares of MacroGenics by 595.0% during the 3rd quarter. Squarepoint Ops LLC now owns 385,633 shares of the biopharmaceutical company’s stock valued at $648,000 after acquiring an additional 330,150 shares during the period. Voleon Capital Management LP bought a new position in shares of MacroGenics during the 3rd quarter valued at approximately $516,000. JPMorgan Chase & Co. grew its position in shares of MacroGenics by 64.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 755,245 shares of the biopharmaceutical company’s stock valued at $1,269,000 after acquiring an additional 295,108 shares during the period. Finally, Amundi bought a new position in shares of MacroGenics during the 1st quarter valued at approximately $272,000. 96.89% of the stock is owned by institutional investors.

MacroGenics Trading Up 6.8%

MGNX opened at $4.53 on Friday. The company has a 50 day moving average of $3.33 and a 200 day moving average of $2.26. The company has a market cap of $287.93 million, a PE ratio of -4.12 and a beta of 1.08. MacroGenics, Inc. has a 12 month low of $1.18 and a 12 month high of $4.64.

MacroGenics (NASDAQ:MGNX) last released its quarterly earnings data on Wednesday, May 13th. The biopharmaceutical company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.01). The business had revenue of $20.78 million during the quarter, compared to the consensus estimate of $15.24 million. MacroGenics had a negative return on equity of 147.80% and a negative net margin of 44.79%. Research analysts forecast that MacroGenics, Inc. will post -1.58 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on MGNX. B. Riley Financial raised shares of MacroGenics from a “neutral” rating to a “buy” rating and increased their target price for the company from $3.00 to $9.00 in a research report on Friday, April 10th. Citigroup reissued a “market perform” rating on shares of MacroGenics in a research report on Tuesday, February 24th. Barclays increased their target price on shares of MacroGenics from $4.00 to $6.00 and gave the company an “overweight” rating in a research report on Monday, April 20th. Wall Street Zen raised shares of MacroGenics from a “sell” rating to a “hold” rating in a report on Saturday, March 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MacroGenics in a report on Friday, May 8th. Three analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $5.50.

MacroGenics Profile

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody–based therapeutics for the treatment of cancer and autoimmune diseases. The company leverages proprietary Fc engineering technologies to enhance immune engagement and extend the activity of its antibodies. Since its founding in 2000, MacroGenics has advanced several product candidates through clinical trials, most notably margetuximab, a HER2-targeted antibody designed to improve outcomes in patients with HER2-positive breast cancer.

Central to MacroGenics’ research platform are its ADAPTIR and Trident bispecific antibody technologies.